NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.93 +0.24 (+2.76 %)
(As of 05/24/2018 02:28 AM ET)
Previous Close$8.93
Today's Range$8.69 - $9.32
52-Week Range$7.70 - $15.20
Volume375,530 shs
Average Volume377,370 shs
Market Capitalization$220.62 million
P/E Ratio-3.08
Dividend YieldN/A
Beta1.36

About Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals logoSyndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio7.06
Quick Ratio7.06

Price-To-Earnings

Trailing P/E Ratio-3.08
Forward P/E Ratio-2.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.11 million
Price / Sales104.58
Cash FlowN/A
Price / CashN/A
Book Value$3.52 per share
Price / Book2.54

Profitability

EPS (Most Recent Fiscal Year)($2.90)
Net Income$-60,800,000.00
Net Margins-3,081.07%
Return on Equity-67.69%
Return on Assets-52.09%

Miscellaneous

Employees44
Outstanding Shares24,710,000

Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.79) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.96) by $0.17. The business had revenue of $0.38 million for the quarter. Syndax Pharmaceuticals had a negative net margin of 3,081.07% and a negative return on equity of 67.69%. View Syndax Pharmaceuticals' Earnings History.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Syndax Pharmaceuticals.

What price target have analysts set for SNDX?

6 equities research analysts have issued 12-month price targets for Syndax Pharmaceuticals' stock. Their predictions range from $20.00 to $40.00. On average, they expect Syndax Pharmaceuticals' share price to reach $26.1667 in the next twelve months. View Analyst Ratings for Syndax Pharmaceuticals.

Who are some of Syndax Pharmaceuticals' key competitors?

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the folowing people:
  • Dr. Briggs W. Morrison, CEO & Director (Age 58)
  • Mr. Michael A. Metzger, Pres & COO (Age 47)
  • Mr. Richard P. Shea, CFO, Treasurer & Principal Accounting Officer (Age 66)
  • Dr. Michael L. Meyers M.D., Ph.D., Chief Medical Officer and Sr. VP (Age 67)
  • Dr. Peter Ordentlich, Co-Founder & CTO (Age 49)

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Has Syndax Pharmaceuticals been receiving favorable news coverage?

Media headlines about SNDX stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 0.05 on Accern's scale. They also gave news coverage about the company an impact score of 47.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.17%), JPMorgan Chase & Co. (1.73%), Dimensional Fund Advisors LP (1.61%), Millennium Management LLC (1.38%), Point72 Asset Management L.P. (1.21%) and Sphera Funds Management LTD. (1.21%). View Institutional Ownership Trends for Syndax Pharmaceuticals.

Which major investors are selling Syndax Pharmaceuticals stock?

SNDX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Northern Trust Corp. View Insider Buying and Selling for Syndax Pharmaceuticals.

Which major investors are buying Syndax Pharmaceuticals stock?

SNDX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Opaleye Management Inc., Dimensional Fund Advisors LP, BlackRock Inc., Asymmetry Capital Management L.P., Sphera Funds Management LTD., JPMorgan Chase & Co. and Sofinnova Ventures Inc. View Insider Buying and Selling for Syndax Pharmaceuticals.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $8.93.

How big of a company is Syndax Pharmaceuticals?

Syndax Pharmaceuticals has a market capitalization of $220.62 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


MarketBeat Community Rating for Syndax Pharmaceuticals (SNDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Syndax Pharmaceuticals in the last 12 months. Their average twelve-month price target is $26.1667, suggesting that the stock has a possible upside of 193.02%. The high price target for SNDX is $40.00 and the low price target for SNDX is $20.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.1667$26.1667$26.4286$24.2857
Price Target Upside: 193.02% upside116.25% upside189.15% upside122.80% upside

Syndax Pharmaceuticals (NASDAQ:SNDX) Consensus Price Target History

Price Target History for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ:SNDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$25.00 ➝ $24.00HighView Rating Details
1/18/2018B. RileyReiterated RatingBuy$40.00HighView Rating Details
8/14/2017InstinetReiterated RatingBuy$27.00 ➝ $22.00LowView Rating Details
8/11/2017CitigroupSet Price TargetBuy$24.00 ➝ $20.00MediumView Rating Details
8/11/2017NomuraLower Price TargetBuy$27.00 ➝ $22.00MediumView Rating Details
8/11/2017OppenheimerBoost Price TargetOutperform$29.00HighView Rating Details
5/19/2017CowenReiterated RatingOutperformLowView Rating Details
3/16/2017FBR & CoInitiated CoverageOutperform ➝ Outperform$27.00HighView Rating Details
12/30/2016BTIG ResearchInitiated CoverageBuy$25.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/7/2016GuggenheimInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Syndax Pharmaceuticals (NASDAQ:SNDX) Earnings History and Estimates Chart

Earnings by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ:SNDX) Earnings Estimates

2018 EPS Consensus Estimate: ($3.95)
2019 EPS Consensus Estimate: ($2.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.20)($0.89)($1.05)
Q2 20182($1.07)($0.83)($0.95)
Q3 20182($1.07)($0.83)($0.95)
Q4 20182($1.17)($0.83)($1.00)
Q1 20191($0.73)($0.73)($0.73)
Q2 20191($0.69)($0.69)($0.69)
Q3 20191($0.65)($0.65)($0.65)
Q4 20191($0.61)($0.61)($0.61)

Syndax Pharmaceuticals (NASDAQ SNDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.88)N/AView Earnings Details
5/8/2018Q1 2018($0.96)($0.79)$0.38 millionViewN/AView Earnings Details
3/5/2018Q4 2017($0.76)($0.80)$0.75 million$1.19 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.80)($0.68)$0.30 million$0.31 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.79)($0.70)$0.31 million$0.31 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.74)($0.71)$0.31 million$0.31 millionViewListenView Earnings Details
3/2/2017Y 2016($0.70)($0.59)$0.31 millionViewListenView Earnings Details
11/10/2016Q3 2016($0.81)($0.84)$0.31 millionViewN/AView Earnings Details
8/9/2016Q216($0.54)($0.47)$0.31 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($2.85)$0.31 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Syndax Pharmaceuticals (NASDAQ:SNDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.90%
Institutional Ownership Percentage: 69.55%
Insider Trading History for Syndax Pharmaceuticals (NASDAQ:SNDX)
Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018Peter OrdentlichInsiderSell7,500$15.00$112,500.00View SEC Filing  
5/17/2017Peter OrdentlichInsiderSell5,000$15.00$75,000.005,000View SEC Filing  
3/8/2016Ivor RoystonDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Syndax Pharmaceuticals (NASDAQ SNDX) News Headlines

Source:
DateHeadline
Syndax: One Step Backward, Two Forward?Syndax: One Step Backward, Two Forward?
seekingalpha.com - May 23 at 4:40 PM
A Requested Update On SyndaxA Requested Update On Syndax
seekingalpha.com - May 23 at 8:49 AM
Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Time?Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Time?
seekingalpha.com - May 21 at 9:18 AM
Blog Exposure - Syndax Pharma Shares Results of Phase-2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDABlog Exposure - Syndax Pharma Shares Results of Phase-2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA
finance.yahoo.com - May 21 at 9:18 AM
Syndax Pharmaceuticals: What Investors Can Expect From This Potential Grower?Syndax Pharmaceuticals: What Investors Can Expect From This Potential Grower?
seekingalpha.com - May 18 at 4:43 PM
Syndax Pharmaceuticals (SNDX) Rating Lowered to Sell at ValuEngineSyndax Pharmaceuticals (SNDX) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - May 17 at 10:23 PM
Syndax down 22% on mid-stage entinostat dataSyndax down 22% on mid-stage entinostat data
seekingalpha.com - May 17 at 4:40 PM
Syndax Pharmaceuticals Presents Updated Phase 2 Cancer-Drug Test ResultsSyndax Pharmaceuticals Presents Updated Phase 2 Cancer-Drug Test Results
www.nasdaq.com - May 17 at 9:21 AM
Syndax (SNDX) Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDASyndax (SNDX) Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA
www.streetinsider.com - May 17 at 9:21 AM
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)
finance.yahoo.com - May 17 at 9:21 AM
Zacks Investment Research Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"Zacks Investment Research Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"
www.americanbankingnews.com - May 15 at 2:09 PM
Syndax Pharmaceuticals Inc. Forecasted to Post Q2 2018 Earnings of ($0.83) Per Share (SNDX)Syndax Pharmaceuticals Inc. Forecasted to Post Q2 2018 Earnings of ($0.83) Per Share (SNDX)
www.americanbankingnews.com - May 14 at 1:40 AM
Oppenheimer Weighs in on Syndax Pharmaceuticals Inc.s Q2 2018 Earnings (SNDX)Oppenheimer Weighs in on Syndax Pharmaceuticals Inc.'s Q2 2018 Earnings (SNDX)
www.americanbankingnews.com - May 14 at 1:40 AM
Syndax Pharmaceuticals: Is This A Multi-Bagger In The Making?Syndax Pharmaceuticals: Is This A Multi-Bagger In The Making?
seekingalpha.com - May 13 at 4:49 PM
Edited Transcript of SNDX earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of SNDX earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:27 AM
Syndax Pharmaceuticals (SNDX) Rating Lowered to Sell at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:23 PM
Syndax Pharmaceuticals (SNDX) Issues Quarterly  Earnings ResultsSyndax Pharmaceuticals (SNDX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 2:38 PM
Syndax Pharmaceuticals beats by $0.17, misses on revenueSyndax Pharmaceuticals beats by $0.17, misses on revenue
seekingalpha.com - May 9 at 9:14 AM
Syndax Pharmaceuticals (SNDX) CEO Briggs Morrison on Q1 2018 Results - Earnings Call TranscriptSyndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:14 AM
Syndax: 1Q Earnings SnapshotSyndax: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:14 AM
Syndax Pharmaceuticals Inc (SNDX) Expected to Announce Earnings of -$1.02 Per ShareSyndax Pharmaceuticals Inc (SNDX) Expected to Announce Earnings of -$1.02 Per Share
www.americanbankingnews.com - May 9 at 3:10 AM
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - May 8 at 4:44 PM
Syndax Pharmaceuticals (SNDX) Upgraded to Hold by ValuEngineSyndax Pharmaceuticals (SNDX) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 2 at 6:12 PM
Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018
finance.yahoo.com - May 1 at 9:07 AM
Syndax Pharmaceuticals (SNDX) Scheduled to Post Quarterly Earnings on MondaySyndax Pharmaceuticals (SNDX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 8:17 AM
Syndax Pharmaceuticals Inc (SNDX) Given Average Recommendation of "Buy" by AnalystsSyndax Pharmaceuticals Inc (SNDX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 5:30 AM
Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual MeetingSyndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - April 25 at 4:41 PM
Syndax to Present at the 2018 American Association for Cancer Research Annual MeetingSyndax to Present at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 21 at 9:02 AM
ValuEngine Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"ValuEngine Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"
www.americanbankingnews.com - April 20 at 12:45 PM
Syndax Pharmaceuticals (SNDX) Downgraded by ValuEngineSyndax Pharmaceuticals (SNDX) Downgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:55 PM
Syndax Pharmaceuticals (SNDX) Downgraded to "D" at TheStreetSyndax Pharmaceuticals (SNDX) Downgraded to "D" at TheStreet
www.americanbankingnews.com - April 17 at 8:17 AM
Syndax Pharmaceuticals Inc (SNDX) Sees Large Drop in Short InterestSyndax Pharmaceuticals Inc (SNDX) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 15 at 1:14 AM
Technical Perspectives on Biotech Stocks -- Syndax Pharma, Teligent ...Technical Perspectives on Biotech Stocks -- Syndax Pharma, Teligent ...
www.prnewswire.com - April 11 at 4:39 PM
Syndax Pharmaceuticals (SNDX) Downgraded by BidaskClubSyndax Pharmaceuticals (SNDX) Downgraded by BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM
Syndax Pharmaceuticals (SNDX) Downgraded by Zacks Investment Research to "Hold"Syndax Pharmaceuticals (SNDX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 6 at 10:54 PM
Syndax Pharmaceuticals Inc (SNDX) Given Average Rating of "Buy" by BrokeragesSyndax Pharmaceuticals Inc (SNDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 5:36 AM
Peter Ordentlich Sells 7,500 Shares of Syndax Pharmaceuticals Inc (SNDX) StockPeter Ordentlich Sells 7,500 Shares of Syndax Pharmaceuticals Inc (SNDX) Stock
www.americanbankingnews.com - April 3 at 10:46 PM
Syndax Pharmaceuticals (SNDX) Lifted to "Buy" at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:48 PM
Syndax Pharmaceuticals (SNDX) Raised to "Hold" at BidaskClubSyndax Pharmaceuticals (SNDX) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 26 at 10:59 PM
Syndax Pharmaceuticals (SNDX) Upgraded at BidaskClubSyndax Pharmaceuticals (SNDX) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM
Syndax Pharmaceuticals (SNDX) Upgraded to "Sell" by ValuEngineSyndax Pharmaceuticals (SNDX) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - March 21 at 12:14 AM
 Analysts Anticipate Syndax Pharmaceuticals Inc (SNDX) Will Announce Earnings of -$1.02 Per Share Analysts Anticipate Syndax Pharmaceuticals Inc (SNDX) Will Announce Earnings of -$1.02 Per Share
www.americanbankingnews.com - March 18 at 9:10 PM
Here's Why Syndax Pharmaceuticals Is Soaring TodayHere's Why Syndax Pharmaceuticals Is Soaring Today
finance.yahoo.com - March 14 at 4:41 PM
Syndax Pharmaceuticals (SNDX) Price Target Lowered to $24.00 at Morgan StanleySyndax Pharmaceuticals (SNDX) Price Target Lowered to $24.00 at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:12 AM
Syndax Pharmaceuticals Inc (SNDX) Receives Consensus Rating of "Buy" from AnalystsSyndax Pharmaceuticals Inc (SNDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 5:27 AM
Syndax Pharmaceuticals Inc (SNDX) to Post Q1 2018 Earnings of ($1.20) Per Share, Oppenheimer ForecastsSyndax Pharmaceuticals Inc (SNDX) to Post Q1 2018 Earnings of ($1.20) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - March 9 at 7:26 AM
B. Riley Equities Analysts Lower Earnings Estimates for Syndax Pharmaceuticals Inc (SNDX)B. Riley Equities Analysts Lower Earnings Estimates for Syndax Pharmaceuticals Inc (SNDX)
www.americanbankingnews.com - March 8 at 6:31 AM
B. Riley Comments on Syndax Pharmaceuticals Incs Q1 2019 Earnings (SNDX)B. Riley Comments on Syndax Pharmaceuticals Inc's Q1 2019 Earnings (SNDX)
www.americanbankingnews.com - March 7 at 1:28 PM
Syndax Pharmaceuticals (SNDX) Posts  Earnings Results, Misses Expectations By $0.04 EPSSyndax Pharmaceuticals (SNDX) Posts Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - March 6 at 8:30 AM
Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - March 5 at 4:49 PM

SEC Filings

Syndax Pharmaceuticals (NASDAQ:SNDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Syndax Pharmaceuticals (NASDAQ SNDX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.